16 results on '"Poettgen C"'
Search Results
2. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
3. OC-0493: Pretreatment metabolic volume in PET: Prognostic in lung cancer? German ESPATUE randomised phase3trial
4. SP-0010: The gains to be made by combined modality treatment in NSCLC: setting the scene of new possibilities
5. EP04.02-005 First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival.
6. MA06.08 Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLC.
7. SP-0018: Oesophageal cancer.
8. Postpneumonectomy Radical Accelerated (Re-)irradiation and Concurrent Chemotherapy for Patients With Contralateral Central Lung Cancer Relapses
9. Accelerated Hyperfractionated Radiation Therapy Within Trimodality Therapy Concepts for Stage IIIa/b Non-small Cell Lung Cancer: Markedly Higher Rate of Pathologic Complete Remissions Than With Conventionally Fractionated Radiochemotherapy
10. Is PET/CT Response of Prognostic Value in Intensified Definitive Chemoradiation for Locally Advanced Non–small Cell Lung Cancer?
11. Mitomycin-C and 5-Fluoro-Uracil Containing Chemotherapy With Concurrent Hyperfractionated Accelerated RadioTherapy (C-HART) of 70.6 Gy Is More Effective than Dose Escalated HART of 77.6 Gy Alone–10 Year Results of the German Multicenter Phase III Randomized Trial (ARO 95-06)
12. 46: Correlation of Residual SUV in Preoperative18F-FDG-PET/CT-Scans With Clinical and Histopathological Findings After Neoadjuvant Chemo-Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
13. PET-CT for Patients (pts) Selection within a Multimodality Treatment Protocol (CTx + CTx/RTx ± S) in Pts with Locally Advanced (LAD) Non-Small Cell Lung Cancer (NSCLC)(Inoperable Stage IIIA/Selected IIIB)
14. OC-0563: 10 years' results of the ARO 95-06 trial of concurrent 70.6 Gy HART/MMC/5-FU versus 77.6 Gy HART alone in LASCC of the H&N.
15. Prognostic Value of Metabolic Tumor Volume after Induction Chemotherapy in Stage IIIA/B Non-Small-Cell Lung Cancer – Secondary Analysis of a Randomized Phase 3 Trial.
16. PP 35 Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer (NSCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.